<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03159559</url>
  </required_header>
  <id_info>
    <org_study_id>TJH-CV-Lipo-PGE1-1</org_study_id>
    <nct_id>NCT03159559</nct_id>
  </id_info>
  <brief_title>PGE1 Improves Coronary Microcirculation Dysfunction in Patients With CAD and Diabetes</brief_title>
  <official_title>A Randomized, Open-label Single-center Trial of Lipo-prostaglandin E1 Improves Coronary Microcirculation Dysfunction in Patients With Ischemic Heart Disease Combine With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <brief_summary>
    <textblock>
      This study is undertaken to determine if intravenous Lipo-PGE1 therapy would improve coronary&#xD;
      microvascular perfusion in patients with ischemic heart disease by CMRI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>myocardial perfusion reserve index (MPRI)</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Coronary Microvascular Perfusion in Patients With Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the treatment group ,patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days ;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In the control group, patients received conventional therapy only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipo-PGE1</intervention_name>
    <description>Patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>aspirin</other_name>
    <other_name>clopidogrel</other_name>
    <other_name>antidiabetic drugs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients giving written consent after being provided with sufficient explanation about&#xD;
             participation in this clinical trial&#xD;
&#xD;
          2. Patients aged between 35-70, no limitation on gender&#xD;
&#xD;
          3. Patients with significant CAD and no need to PCI: 50%-70% luminal stenosis as&#xD;
             determined by diagnostic coronary angiography, and left main coronary artery stenosis&#xD;
             less than 50%; no history of revascularization procedures before&#xD;
&#xD;
          4. MPRI&lt;2.0&#xD;
&#xD;
          5. Type 2 DM patients with glycosylated hemoglobin levels&gt;7%&#xD;
&#xD;
          6. All patients were PGE1-naive, defined as receiving no PGE1 therapy for more than 7&#xD;
             days during the previous 12 months&#xD;
&#xD;
          7. Hypertension remained stable for last 3 months, patients with controlled BP level:&#xD;
             SBP&lt;160mmHg and DBP&lt;95mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a history of allergic to PGE1 or a history of prior PGE1 treatment.&#xD;
&#xD;
          2. History of revascularization procedures before: PCI or CABG&#xD;
&#xD;
          3. Patients with implanted pacemaker or ICD, ventricular assist device and intra-aortic&#xD;
             balloon counter pulsation pump&#xD;
&#xD;
          4. Patients who have experienced myocardial infarction&#xD;
&#xD;
          5. Patients with serious systolic left ventricular function failure: echocardiography&#xD;
             EF&lt;25%&#xD;
&#xD;
          6. Claustrophobia&#xD;
&#xD;
          7. Patients who used Insulin pumps&#xD;
&#xD;
          8. SBP&lt;90mmHg&#xD;
&#xD;
          9. Chronic renal function failure: creatinine level &gt;2.5mg/dl or 221umol/l&#xD;
&#xD;
         10. Patients with serious or frequent arrhythmia ,atrial fibrillation、frequent ventricular&#xD;
             premature contraction、sick sinus syndrome, second- or third degree atrioventricular&#xD;
             block&#xD;
&#xD;
         11. Prior non-cardiac illness with estimated life expectancy &lt;2-yrs&#xD;
&#xD;
         12. Women who are pregnant, lactation,or maybe pregnant in the study period&#xD;
&#xD;
         13. Unable to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Dao Wen Wang</investigator_full_name>
    <investigator_title>Chair of Internal medicine Dept. and Cardiovascular Division</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
    <mesh_term>Alprostadil</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

